Trial Profile
Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms BOTTOM-Study
- 10 Sep 2018 Status changed from recruiting to discontinued.
- 28 Mar 2017 Planned number of patients changed from 70 to 40.
- 03 Sep 2013 New trial record